Skip to content

Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder

TerminatedNot applicableNCT03538444
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

This double-blind, randomized, controlled trials will investigate the effect of accelerated, repeated transcranial magnetic stimulation on opiate craving and perceived pain .

Study details

Official title
A Double-Blind, Randomized, Controlled Trial, Utilizing Accelerated Repetitive Transcranial Magnetic Stimulation (rTMS) as a Tool to Decrease Pain and Craving in Hospitalized Patients With Opiate Use Disorder
Conditions
Sponsor
Medical University of South Carolina
Start date
2018-09-28
Primary completion
2020-05-01
Sex
All
Age range
from 18 Years to 65 Years
Results posted
Yes, on ClinicalTrials.gov
Countries
United States
Total sites listed
1

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Participants must be able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments. 2. Participants must meet DSM-5 criteria for moderate or severe OUD. While individuals may also meet criteria for use disorders of other substances (with the exception of alcohol or benzodiazepines), they must identify prescription opiates as their primary substance of abuse. 3. Participants must be admitted to the inpatient unit for opiate detoxification. 4. Participants must consent to random assignment. Exclusion Criteria: 1. Participants who are pregnant will be excluded. 2. Participants with a history of/or current psychotic disorder will be excluded. 3. Participants with a history of dementia or other cognitive impairment will be excluded. 4. Participants with active suicidal ideation, or a suicide attempt within the past 90 days will be excluded. 5. Participants with contraindications to receiving rTMS (including a history of seizures, or any implanted metal above the neck) will be excluded. 6. Those with unstable general medical conditions will be excluded. 7. Those who are currently using naltrexone, or tramadol, will be excluded. 8. Those with alcohol or benzodiazepine use disorders will be excluded due to increased risk of seizure.

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03538444